logo
logo
TFX stock ticker logo

Teleflex Incorporated

NYSE•TFX
CEO: Mr. Liam J. Kelly
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1980-03-17
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Contact Information
550 East Swedesford Road, Suite 400, Wayne, PA, 19087-1603, United States
610-225-6800
www.teleflex.com
Market Cap
$5.43B
P/E (TTM)
-6.0
26.9
Dividend Yield
1.1%
52W High
$143.32
52W Low
$100.18
52W Range
53%
Rank29Top 17.8%
5.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$568.98M+0.00%
4-Quarter Trend

EPS

-$16.15+0.00%
4-Quarter Trend

FCF

$151.56M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Continuing Revenue Growth Net revenues reached $1.99B USD, increasing 17.2% driven by $202.4M contribution from the acquired VI Business.
Major Acquisition Completed Completed $825.2M cash acquisition of BIOTRONIK VI business in Q3 2025, adding coronary and peripheral devices.
Significant Asset Impairment Recognized $100.0M impairment charge on Titan SGS intangible assets following a downward revision to future sales forecasts.
Leadership Transition Finalized Stuart Randle appointed Interim President and CEO in January 2026 following the departure of former Chairman Kelly.

Risk Factors

Gross Margin Compression Gross margin dropped 480 basis points to 56.2% due to amortization from VI acquisition and increased logistics costs.
Strategic Divestiture Execution Sale of three major businesses is subject to closing adjustments and regulatory approvals expected in the second half of 2026.
Sterilization Supply Chain Risk Disruptions at contract sterilizers using ethylene oxide could impair ability to supply critical medical products.
Competitive Market Pressures Industry consolidation and customer purchasing power may compel price reductions, negatively affecting financial results.

Outlook

Portfolio Transformation Underway Agreements signed to sell Acute Care, IU, and OEM businesses for $2.0B cash, expected to close in second half 2026.
Integration Savings Targeted VI Business integration plan estimates $36M to $44M total charges, aiming for $24M to $30M annual pre-tax savings.
Capital Return Strategy Intend to use net divestiture proceeds, approximately $1.8B after-tax, for debt paydown and shareholder repurchases.
ERP System Upgrade Initiated Multi-year phased conversion to upgrade global ERP system is underway, requiring significant personnel and financial resources.

Peer Comparison

Revenue (TTM)

OSCR stock ticker logoOSCR
$11.70B
+27.5%
BLCO stock ticker logoBLCO
$5.10B
+6.5%
BRKR stock ticker logoBRKR
$3.44B
+2.1%

Gross Margin (Latest Quarter)

ARWR stock ticker logoARWR
100.0%
+50.6pp
PTCT stock ticker logoPTCT
90.1%
-49.4pp
KRYS stock ticker logoKRYS
89.8%
+2.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ARWR$9.01B44.536.1%19.5%
PCVX$8.90B-11.0-25.9%7.5%
KRYS$7.57B36.618.7%0.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-6.7%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:Apr 29, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data